CompletedNCT00640510
A Study Comparing Rapid Acting Intramuscular Olanzapine and Placebo in Agitated Patients With Schizophrenia
Researchers compared Rapid Acting Intramuscular Olanzapine and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Medication studyAges 20–64Japan
Understand this study
What did researchers investigate?
Researchers compared Rapid Acting Intramuscular Olanzapine and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 20 years to 64 years. Other eligibility criteria applied.
- Listed locations
- Fukushima and 10 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMarch 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 34
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Japan
- Age range
- From 20 Years to 64 Years
- Official registry ID
- NCT00640510
- Official title
Show the full official title
A Placebo-Controlled, Double-Blind Confirmatory Study of Rapid-Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia
Recruitment & locations
CompletedFukushima · Gunma · Kagoshima
8 more locations
- Kanagawa
- Kumamoto
- Okayama
- Okinawa
- Saga
- Tokyo
- Tottori
- Yamagata
Questions about this study
What did researchers investigate?
Researchers compared Rapid Acting Intramuscular Olanzapine and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Rapid Acting Intramuscular Olanzapine and Isotonic sodium chloride solution.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 20 years to 64 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me